Holen Sie sich die Stockscreener-App
31.11
0.16%
0.05
Handel nachbörslich:
31.19
0.08
+0.26%
Schlusskurs vom Vortag:
$31.06
Offen:
$31.49
24-Stunden-Volumen:
354.15K
Relative Volume:
0.79
Marktkapitalisierung:
$1.45B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-38.24
EPS:
-0.8135
Netto-Cashflow:
-
1W Leistung:
-10.45%
1M Leistung:
-30.40%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$30.06
$31.49
1-Wochen-Bereich:
$29.63
$34.41
52-Wochen-Spanne:
$23.00
$55.42
Hemab Therapeutics Holdings Inc Stock (COAG) Company Profile
Firmenname
Hemab Therapeutics Holdings Inc
Sektor
Branche
Telefon
45 2138 7627
Adresse
101 MAIN STREET, CAMBRIDGE
Compare COAG vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COAG
Hemab Therapeutics Holdings Inc
|
31.11 | 1.62B | 0 | 0 | 0 | -0.8135 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Hemab Therapeutics Holdings Inc Aktie (COAG) Neueste Nachrichten
Hemab Therapeutics (NASDAQ:COAG) Shares Gap DownHere's What Happened - MarketBeat
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Hemab Therapeutics (NASDAQ:COAG) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Hemab Therapeutics Holdings, Inc. (COAG) Stock Price, News, Quote & History - Yahoo! Finance Canada
Hemab Therapeutics: The Market Is Pricing One Rung Of A Four-Rung Ladder (NASDAQ:COAG) - Seeking Alpha
Hemab Therapeutics Holdings (COAG) Joins Russell Indices, Is The Stock Still Trading At A Discount? - Yahoo Finance
76,900 Shares in Hemab Therapeutics Holdings, Inc. $COAG Bought by State Street Corp - MarketBeat
Form 4 Hemab Therapeutics Holdings For: 25 September By Investing.com - Investing.com Canada
Director Walbert Keli's option carries a $35.72 exercise price at Hemab Therapeutics (COAG). - Stock Titan
Walbert Keli is listed as a director of Hemab Therapeutics (COAG) in an initial ownership statement. - Stock Titan
Keli Walbert elected to Hemab board, joins Audit Committee - TradingView
Hemab Therapeutics Holdings, Inc. (COAG) stock price, news, quote and history - uk.finance.yahoo.com
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert - The Manila Times
Hemab Therapeutics (NASDAQ:COAG) Shares Down 5.7%What's Next? - MarketBeat
Hemab Therapeutics Holdings, Inc.(NasdaqGS:COAG) added to S&P Biotechnology Select Industry Index - marketscreener.com
Hemab Therapeutics Holdings, Inc.(NasdaqGS: COAG) added to S&P Global BMI Index - marketscreener.com
Hemab Therapeutics Holdings (Nasdaq:COAG)Stock Analysis - Simply Wall Street
Hemab Therapeutics Holdings, Inc.(NasdaqGS:COAG) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding - The Manila Times
Heavy menstrual bleeding affects 1 in 3 women. Hemab begins testing a new treatment. - Stock Titan
Hemab Therapeutics (NASDAQ:COAG) Shares Up 7.6%Time to Buy? - MarketBeat
Opaleye Management Inc. Makes New Investment in Hemab Therapeutics Holdings, Inc. $COAG - MarketBeat
Hemab Therapeutics (NASDAQ:COAG) Trading Down 6.8%What's Next? - MarketBeat
Citadel Advisors LLC Takes Position in Hemab Therapeutics Holdings, Inc. $COAG - MarketBeat
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Braidwell LP Purchases New Shares in Hemab Therapeutics Holdings, Inc. $COAG - MarketBeat
Biopharma IPO class of 2026: share price up 66% on average - BioWorld News
Hemab Therapeutics (NASDAQ:COAG) Trading Down 8.4%Here's What Happened - MarketBeat
AppLovin vs. CoreWeave: What Recent Revenue Trends Tell Investors - Yahoo Finance
Capital International Investors Establishes New Position in Hema - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Novo Holdings A/S (COAG) discloses 9.0% beneficial stake in Hemab Therapeutics - Stock Titan
Avoro, Aghazadeh report 7.06% Hemab Therapeutics (COAG) ownership stake - Stock Titan
20 Years of Prix Galien USA Brings a New Nominee Class—Who Wins? - Stock Titan
HC Wainwright Cuts Earnings Estimates for Hemab Therapeutics - MarketBeat
Wedbush Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $64 - Moomoo
Hemab Therapeutics (NASDAQ:COAG) Hits New 52-Week High After Analyst Upgrade - MarketBeat
Hemab Therapeutics (COAG): Capital International Investors discloses 7.7% ownership - Stock Titan
Hemab Therapeutics stock price target raised to $60 by H.C. Wainwright - Investing.com Canada
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
COAG SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
FMR LLC Acquires Stake in Hemab Therapeutics Holdings Inc (COAG) - GuruFocus
H.C. Wainwright Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $60 - Moomoo
Hemab Therapeutics Reports Q2 2026 Financials and Pipeline Progress in Latest 10-Q Filing - Kalkine Media
Hemab Therapeutics (COAG) widens loss but builds $457.5M cash war chest - Stock Titan
Hemab Therapeutics (NASDAQ:COAG) Price Target Raised to $60.00 at HC Wainwright - MarketBeat
Wedbush Adjusts Price Target on Hemab Therapeutics to $64 From $55, Keeps Outperform Rating - marketscreener.com
Form 8K Hemab Therapeutics Holdings For: 11 August By Investing.com - Investing.com South Africa
Hemab Therapeutics Gains FDA Backing to Advance Sutacimig Into Phase 3 Trial for Glanzmann Thrombasthenia - Minichart
Hemab Therapeutics' Q2 Net Loss Narrows - marketscreener.com
Earnings Flash (COAG) Hemab Therapeutics Posts Q2 Net Loss $0.80 a Share, vs. FactSet Est of $0.56 Loss - marketscreener.com
Finanzdaten der Hemab Therapeutics Holdings Inc-Aktie (COAG)
Umsatz
Nettogewinn
Free Cashflow
ENV
Hemab Therapeutics Holdings Inc-Aktie (COAG) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
Jun 15 '26 |
Buy |
24.89 |
6,146 |
152,974 |
6,383,114 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 19 '26 |
Buy |
24.97 |
3,802 |
94,936 |
6,375,972 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 20 '26 |
Buy |
24.94 |
996 |
24,840 |
6,376,968 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 12 '26 |
Buy |
24.90 |
6,387 |
159,036 |
6,372,170 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 11 '26 |
Buy |
24.81 |
39,869 |
989,226 |
6,365,783 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 07 '26 |
Buy |
24.46 |
9,906 |
242,323 |
6,324,431 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 08 '26 |
Buy |
24.98 |
1,483 |
37,045 |
6,325,914 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
May 04 '26 |
Buy |
18.00 |
2,675,000 |
48,150,000 |
6,149,096 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
May 05 '26 |
Buy |
24.63 |
97,411 |
2,399,546 |
6,246,507 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
May 06 '26 |
Buy |
24.60 |
68,018 |
1,673,399 |
6,314,525 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):